Isaac Francis

Tokenised stock holders more than doubled to 1.31 million over the past month, according to RWA.xyz data.

Meta (NASDAQ:META) deactivated 756,000 underage accounts as platforms navigate Australia's nationwide under-16 social media ban.

• Hardware wallet sales in Russia have more than doubled, pointing to stronger demand for self-custody.
• The trend is also visible across major hardware wallet providers, with users increasingly moving assets off exchanges.
• The main risk remains self-custody responsibility, including device security and recovery phrase management.

• CoreWeave (NASDAQ:CRWV) reported Q2 2026 revenue of $2.58 billion, more than doubling year over year, with revenue backlog reaching approximately $104 billion.
• The company reported adjusted EBITDA of $1.51 billion, while GAAP net loss widened to about $626 million as infrastructure investment continued.
• AI cloud providers are expanding computing capacity through financing, customer partnerships, and specialized infrastructure while managing high capital requirements.

• Neutrl halted redemptions for its US$486 million NUSD stablecoin after reserve concerns emerged around its exposure to Resolv.
• The situation has drawn attention to reserve transparency, collateral structures, and liquidity risks across decentralised stablecoin projects.
• Reserve quality and redemption access remain the key factors separating more resilient stablecoin models from structurally weaker ones.

Teamshares (NASDAQ:TMS) reported second-quarter revenue of $148.7 million, up 20%, while net income improved to $9.5 million from a $12.9 million loss.

SurgePays (NASDAQ:SURG) reported Q2 revenue of $16.2 million, up 40.7%, while net income available to common stockholders reached $1.29 million.

Core Scientific (NASDAQ:CORZ) completed its $444 million cash acquisition of Polaris DS, securing approximately 440 MW of active grid-connected power capacity in Oklahoma.

UTStarcom (NASDAQ:UTSI) reported first-half 2026 revenue of $3.4 million, down about 26% as equipment and service sales declined.

Pfizer (NYSE:PFE) and Valneva (NASDAQ:VALN) said the EMA validated their PF-07307405 Lyme vaccine application after Phase 3 efficacy exceeded 70%.